149,285 Vaxcyte, Inc. $PCVX Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA reduced its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 21.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 545,434 shares of the company’s stock after selling 149,285 shares during the period. Pictet Asset Management Holding SA owned 0.37% of Vaxcyte worth $31,035,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. IFP Advisors Inc lifted its position in shares of Vaxcyte by 72.8% in the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after buying an additional 236 shares during the last quarter. Manchester Capital Management LLC acquired a new position in shares of Vaxcyte during the 3rd quarter valued at about $47,000. Covestor Ltd increased its holdings in shares of Vaxcyte by 31.1% during the 3rd quarter. Covestor Ltd now owns 939 shares of the company’s stock valued at $53,000 after acquiring an additional 223 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Vaxcyte by 68.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,248 shares of the company’s stock valued at $73,000 after acquiring an additional 507 shares in the last quarter. Finally, Allworth Financial LP bought a new position in shares of Vaxcyte in the 2nd quarter valued at approximately $75,000. 96.78% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Vaxcyte

In related news, CAO Elvia Cowan sold 3,000 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $60.92, for a total transaction of $182,760.00. Following the transaction, the chief accounting officer owned 27,860 shares of the company’s stock, valued at approximately $1,697,231.20. The trade was a 9.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jim Wassil sold 2,250 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $60.90, for a total transaction of $137,025.00. Following the completion of the sale, the executive vice president directly owned 145,435 shares of the company’s stock, valued at approximately $8,856,991.50. This trade represents a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 50,692 shares of company stock worth $4,032,875. 3.30% of the stock is currently owned by corporate insiders.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX opened at $66.36 on Wednesday. The business has a 50 day moving average price of $61.98 and a 200 day moving average price of $57.47. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.56 and a current ratio of 4.56. Vaxcyte, Inc. has a twelve month low of $42.40 and a twelve month high of $90.75.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.99) EPS for the quarter, topping the consensus estimate of ($2.11) by $0.12. During the same period in the prior year, the company earned ($1.56) earnings per share. As a group, equities analysts predict that Vaxcyte, Inc. will post -7.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PCVX. Guggenheim boosted their target price on Vaxcyte from $116.00 to $125.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $120.00 target price on shares of Vaxcyte in a research note on Monday, October 12th. Needham & Company LLC lifted their target price on shares of Vaxcyte from $110.00 to $122.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Finally, Bank of America cut their target price on shares of Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a research report on Monday, September 28th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $110.50.

About Vaxcyte

Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response. The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.